In this episode, Dr. Vignesh Packiam is joined by Dr. Sima Porten and Dr. Patrick Hensley to discuss how the ongoing BCG shortage is reshaping treatment conversations for patients newly diagnosed with non–muscle invasive bladder cancer (NMIBC). The discussion emphasizes shared decision-making, outlining how clinicians can navigate evolving intravesical therapy options and guide patients through a more complex treatment landscape than ever before.
Contributors:
Dr. Patrick Hensley is a urologic oncologist at the University of Kentucky.
Dr. Vignesh Packiam is an associate professor of urologic oncology at Rutgers Cancer Institute of New Jersey.
Dr. Sima Porten is a urologic oncologist with UCSF Health in San Francisco, California.
